BioSpace News Archive

BioAgilytix, a leading global contract research organization, announced an agreement to be further capitalized by Cinven, a leading international private investment firm focused on building world-class global companies.

AbbVie announced that the European Commission has approved SKYRIZI® alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying anti-rheumatic drugs.

Inmagene Biopharmaceuticals announced that it has filed two international patent applications for its drug candidates, IMG-007 and IMG-008.

Greenwich LifeSciences, Inc. announced CEO Snehal Patel will participate in the virtual portion of Jefferies’ Annual London Healthcare Conference held from November 16-19, 2021.

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that new Phase 3 data for molnupiravir, an investigational oral COVID-19 antiviral medicine, will be presented as a late-breaking poster at the American Society of Tropical Medicine and Hygiene 2021 Annual Meeting taking place virtually from Nov. 17-21.

ANGLE plc, a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 22,667 new ordinary shares of £0.10 each in the Company.

Santhera Pharmaceuticals and ReveraGen Biopharma announcethe successful completion of a first pre-NDA meeting with the U.S. Food and Drug Administration for vamorolone for the treatment of Duchenne muscular dystrophy.

The global albumin market is likely to be driven by various factors such as the rise in plasma collection, the production of plant-based albumin, and high demand for albumin in research and development activities.

As per a recent report by Transparency Market Research pertaining to global breast cancer therapeutics market states that the market is projected to grow substantially in from 2016 to 2024.

Proteins are biocatalysts and explicit for quickening different sorts of synthetic responses without going through self-changes.